Interleukin 28B genetic polymorphism and hepatitis B virus infection

World Journal of Gastroenterology

Volumn 20, Issue 34, 2014, Pages 12026-12030

  Takahashi, Toru ^a  

^a Department of Internal Medicine   (Japan)

Author keywords

Hepatitis B virus; Interferon; Interleukin 28B; Pegylated interferon; Polymorphism

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT; BIOLOGICAL MARKER; IL28B PROTEIN, HUMAN; INTERFERON; INTERLEUKIN DERIVATIVE;

GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; RECURRENT INFECTION; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; VIRAL CLEARANCE; ANIMAL; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PATHOGENICITY; PHARMACOGENETICS; PHENOTYPE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERONS; INTERLEUKINS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84909579830     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i34.12026     Document Type: Review

References (37)

1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
2. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
3. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]
4. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-145, 1345.e1-7 [PMID: 20060832 DOI: 10.1053/j.gastro.2009.12.056]
6. World Health Organization. Hepatitis B fact Sheet no. 204. Cited12 April 2012. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
7. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343]
8. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68 [PMID: 12469119]
9. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509 [PMID: 20434452 DOI: 10.1053/j.gastro.2010.04.049]
10. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896 [PMID: 20931559 DOI: 10.1002/hep.23912]
11. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444 [PMID: 15887125]
12. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039 [PMID: 18467494 DOI: 10.1073/pnas.0707882105]
13. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, Rice CM, Dustin LB. Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 2011; 54: 1913-1923 [PMID: 21800339 DOI: 10.1002/hep.24580]
14. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854 [PMID: 15731279]
15. Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication. J Viral Hepat 2013; 20: 281-289 [PMID: 23490373 DOI: 10.1111/j.1365-2893.2012.01649.x]
16. Nakagawa S, Hirata Y, Kameyama T, Tokunaga Y, Nishito Y, Hirabayashi K, Yano J, Ochiya T, Tateno C, Tanaka Y, Mizokami M, Tsukiyama-Kohara K, Inoue K, Yoshiba M, Takaoka A, Kohara M. Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection. PLoS One 2013; 8: e59611 [PMID: 23555725 DOI: 10.1371/journal.pone.0059611]
17. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-832 [PMID: 20564352 DOI: 10.1002/hep.23743]
18. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology 2013; 144: 414-425.e7 [PMID: 23089201 DOI: 10.1053/gastro.2012.10.034]
19. Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, Takehara T. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 2013; 57: 1705-1715 [PMID: 23213063 DOI: 10.1002/hep.26182]
20. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749-1753 [PMID: 20977343 DOI: 10.1086/657146]
21. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, Pan Y, Zhang H, Jiang J, Niu J. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31: 1118-1126 [PMID: 21745278 DOI: 10.1111/j.1478-3231.2011.02507.x]
22. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH. Effect of host and viral factors on hepatitis B e antigenpositive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir Ther 2011; 16: 629-637 [PMID: 21817184 DOI: 10.3851/IMP1841]
23. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-520.e1 [PMID: 22108195 DOI: 10.1053/j.gastro.2011.11.025]
24. Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, Liu Y. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012; 93: 297-300 [PMID: 22209781 DOI: 10.1016/j.antiviral.2011.12.009]
25. de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 475-481 [PMID: 22263608 DOI: 10.3109/00365521.2011.648952]
26. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012; 79: 302-305 [PMID: 22239156 DOI: 10.1111/j.1399-0039.2011.01835.x]
27. Martín-Carbonero L, Rallón NI, Benito JM, Poveda E, González-Lahoz J, Soriano V. Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses 2012; 28: 1262-1264 [PMID: 22324878]
28. Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, Chen X, Wei L. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 2012; 61: 1433-1439 [PMID: 22310928 DOI: 10.1007/s00262-012-1203-y]
29. Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L. Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population. Int J Immunogenet 2012; 39: 346-352 [PMID: 22325058 DOI: 10.1111/j.1744-313X.2012.01097.x]
30. Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, Zhang J. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One 2012; 7: e50787 [PMID: 23227209 DOI: 10.1371/journal.pone.0050787]
31. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896 [PMID: 22473858 DOI: 10.1002/hep.25749]
32. Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-1703 [PMID: 23449268 DOI: 10.1093/cid/cit121]
33. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol 2013; 28: 861-866 [PMID: 23301835 DOI: 10.1111/jgh.12110]
34. Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 2013; 56: 84-90 [PMID: 23343781 DOI: 10.1159/000342526]
35. Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS One 2013; 8: e69166 [PMID: 23874902 DOI: 10.1371/journal.pone.0069166]
36. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One 2013; 8: e58071 [PMID: 23469142 DOI: 10.1371/journal.pone.0058071]
37. Jilg N, Chung RT. One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology 2013; 57: 870-872 [PMID: 22911469 DOI: 10.1002/hep.26026]